L-Lactic acid
|
Basic information |
| Metabolite name | L-Lactic acid |
 | HMDB0000190 |
 |
C00186 |
 |
107689 |
| Synonyms | Lactic acid; |
| No. of studies | 96 |
|
Basic information |
| Metabolite name | L-Lactic acid |
| HMDB0000190 |
|
C00186 |
|
107689 |
| Synonyms | Lactic acid; |
| No. of studies | 96 |
|
Relationship between L-Lactic acid and depression (count: 96) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Down |
| Study M002 | Type1 | CUMS group vs. control group | Thalamus | Sprague-Dawley rat | Down |
| Study M013 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M014 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M015 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M015 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M015 | Type2 | CUMS + Xiaoyaosan Bei group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M015 | Type2 | CUMS + Xiaoyaosan Nan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M025 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M030 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M031 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M032 | Type2 | CUMS + high dose of genipin group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M032 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M032 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M032 | Type2 | CUMS + low dose of genipin group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M035 | Type1 | depressed suicide attempters group vs. control group | Plasma | Human | Down |
| Study M043 | Type1 | chronic hepatitis B patients with MDD group vs. without MDD group | Urine | Human | Down |
| Study M047 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M047 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M047 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M049 | Type2 | xiaoyansan treatment 8-week vs. baseline | Urine | Human | Down |
| Study M050 | Type3 | 24h Ketamine group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M055 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M055 | Type2 | CUMS + low dose of genipin group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M055 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M055 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M055 | Type2 | CUMS + high dose of genipin group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M056 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M056 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M056 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M056 | Type2 | CUMS + high dose of FFCGF group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M056 | Type2 | CUMS + middle dose of FFCGF group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M059 | Type1 | depressed group vs. control group | Plasma | Human | Up |
| Study M059 | Type2 | Xiaoyaosan-treated depressed group 12-week vs. baseline | Plasma | Human | Down |
| Study M066 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M070 | Type1 | depressed group vs. non-depressed group | Urine | Human | Up |
| Study M074 | Type1 | sCSDS group vs. control group | Faece | C57BL/6JJmsSlc mouse | Up |
| Study M082 | Type3 | medium dose of DG group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M085 | Type3 | ketamine group vs. control group at 24 h after treatment | Serum | Cynomolgus monkey | Down |
| Study M085 | Type3 | ketamine group vs. control group at 24 h after treatment | Urine | Cynomolgus monkey | Down |
| Study M087 | Type2 | ketamine group 2-h vs. baseline | Plasma | Human | Down |
| Study M094 | Type1 | PSD group vs. stroke and control group | Urine | Human | Down |
| Study M097 | Type1 | depressed women group vs. control women group | Urine | Human | Up |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M102 | Type1 | severe MDD group vs. control group | Urine | Human | Up |
| Study M1044 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M1048 | Type1 | adult high-fat diet group vs. adult control group | Liver | CD-1 mouse | Up |
| Study M1048 | Type1 | juvenile high-fat diet group vs. juvenile control group | Plasma | CD-1 mouse | Down |
| Study M1048 | Type2 | adult high-fat diet + probiotic group vs. adult high-fat diet group | Brain | CD-1 mouse | Up |
| Study M1048 | Type2 | adult high-fat diet + probiotic group vs. adult high-fat diet group | Liver | CD-1 mouse | Up |
| Study M1048 | Type3 | adult probiotic group vs. adult control group | Liver | CD-1 mouse | Up |
| Study M1048 | Type3 | adult probiotic group vs. adult control group | Brain | CD-1 mouse | Up |
| Study M105 | Type1 | sCSDS group vs. control group | Plasma | C57BL/6JJmsSlc mouse | Down |
| Study M1057 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Up |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Down |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell | Rat | Down |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell | Rat | Down |
| Study M1074 | Type1 | MDD group vs. control group | Serum | Human | Up |
| Study M1075 | Type1 | CSDS group vs. control group | Frontal cortex | C57BL/6J mouse | Up |
| Study M1075 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Up |
| Study M1076 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M1076 | Type2 | depression group, post Shuganjieyu treatment vs. baseline | Plasma | Human | Up |
| Study M108 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M108 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + BR group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + BR group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M109 | Type1 | PPD group vs. HC and PPWD group | Urine | Human | Down |
| Study M1092 | Type1 | CMS group vs. control group | Ventral hippocampus | Wistar rat | Down |
| Study M1092 | Type2 | CMS + venlafaxine group vs. CMS group | Ventral hippocampus | Wistar rat | Up |
| Study M1102 | Type1 | nitenpyram group vs. control group, male offspring | Faece | ICR mouse | Down |
| Study M113 | Type1 | CUMS group vs. control group | Serum | Wistar rat | Down |
| Study M114 | Type3 | venlafaxine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M1143 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M1143 | Type2 | MDD group, after 2-week escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M120 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M131 | Type1 | LH group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M131 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M131 | Type1 | SD group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M131 | Type1 | CRS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M133 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M133 | Type2 | CUMS + XY-A group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M134 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M134 | Type2 | CRS + BH group vs. CRS group | Urine | Sprague-Dawley rat | Down |
| Study M140 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M140 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M140 | Type2 | CUMS + paroxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M140 | Type2 | CUMS + SJ group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M146 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + low dose of SSO group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M146 | Type2 | CUMS + high dose of SSO group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M146 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M146 | Type2 | CUMS + middle dose of SSO group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M207 | Type1 | depressed group vs. control group | Faece | Kunming mouse | Down |
| Study M209 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M304 | Type1 | depression group vs. control group | Cerebrospinal fluid | Human | Up |
| Study M323 | Type1 | depression group vs. control group | Cerebrospinal fluid | Human | Up |
| Study M339 | Type1 | depression group vs. control group | Pregenual anterior cingulate cortex | Human | Up |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Up |
| Study M472 | Type3 | S-Ket group vs. control group | PC12 cell | Rat | Down |
| Study M473 | Type1 | high-fat diet group vs. control group | Striatum | C57BL/6J mouse | Up |
| Study M473 | Type1 | high-fat diet group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M479 | Type1 | diabetic depression group vs. control group | Prefrontal cortex | Wistar rat | Up |
| Study M479 | Type1 | diabetic depression group vs. control group | Hippocampus | Wistar rat | Up |
| Study M479 | Type1 | diabetic depression group vs. control group | Hypothalamus | Wistar rat | Up |
| Study M480 | Type1 | sleep deprivation group vs. control group | Urine | Wistar rat | Down |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Unknown |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + low dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M543 | Type1 | summer depression group vs. summer control group | Plasma | Human | Down |
| Study M547 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M556 | Type1 | sleep deprivation group vs. control group | Urine | Wistar rat | Down |
| Study M573 | Type1 | CSDS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Urine | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 40-49 | Plasma | Human | Unknown |
| Study M592 | Type1 | CUMS group vs. control group, NMR | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type2 | CUMS + venlafaxine group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + low dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + high dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M629 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M629 | Type2 | CUMS + middle dose of coumaroylspermidine extract group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M636 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M636 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Faece | Sprague-Dawley rat | Down |
| Study M663 | Type3 | diterpene ginkgolides group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M668 | Type1 | PSD group vs. stroke group | Urine | Human | Down |
| Study M676 | Type1 | CVS group vs. control group | Hippocampus | Wistar rat | Up |
| Study M676 | Type2 | CVS + Chaihu-Shu-Gan-San group vs. CVS group | Hippocampus | Wistar rat | Down |
| Study M685 | Type1 | SDS group vs. control group | Nucleus accumbens | C57BL/6J mouse | Up |
| Study M693 | Type1 | SDS group vs. control group | Plasma | C57BL/6J mouse | Up |
| Study M738 | Type1 | CMS + Xiaoyaosan group vs. CMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M738 | Type1 | CMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M739 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M739 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M740 | Type1 | CUMS group vs. control group | Soleus muscle | Sprague-Dawley rat | Down |
| Study M740 | Type1 | CUMS group vs. control group | Gastrocnemius muscle | Sprague-Dawley rat | Up |
| Study M740 | Type2 | CUMS + endurance exercise group vs. CUMS group | Soleus muscle | Sprague-Dawley rat | Up |
| Study M740 | Type2 | CUMS + endurance exercise group vs. CUMS group | Gastrocnemius muscle | Sprague-Dawley rat | Down |
| Study M757 | Type1 | PSD group vs. stroke group | Urine | Human | Up |
| Study M762 | Type1 | corticosterone group vs. control group | Liver | Wistar rat | Down |
| Study M762 | Type2 | corticosterone + metformin group vs. corticosterone group | Liver | Wistar rat | Up |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M788 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M791 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Cecum | Sprague-Dawley rat | Up |
| Study M809 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Up |
| Study M809 | Type2 | CUMS + Milletia speciosa Champ group vs. CUMS group | Serum | Kunming mouse | Down |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M844 | Type1 | CORT group vs. control group | PC12 cell | Rat | Down |
| Study M873 | Type1 | ovariectomy + CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M873 | Type2 | ovariectomy + CUMS + Xiang-Su volatile oil group vs. ovariectomy + CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M885 | Type1 | CMS-vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M905 | Type1 | subclinical depression group vs. control group | Urine | Human | Down |
| Study M912 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M921 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M966 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M966 | Type2 | CUMS + Xiaoyao San group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M966 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M971 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M971 | Type2 | CUMS + Tao-Hong-Si-Wu decoction group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M971 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |